BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers

被引：0
|
作者：
Zannel Blanchard
Bibbin T Paul
Barbara Craft
Wael M ElShamy
机构：
[1] University of Mississippi Medical Center,Cancer Institute
[2] University of Mississippi Medical Center,Department of Medicine
[3] Present address: University of Connecticut Health Center,undefined
来源：
Breast Cancer Research | / 17卷
关键词：
Epidermal Growth Factor Receptor; Paclitaxel; Triple Negative Breast Cancer; Survivin Expression; Triple Negative Breast Cancer Cell;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
    Blanchard, Zannel
    Paul, Bibbin T.
    Craft, Barbara
    ElShamy, Wael M.
    BREAST CANCER RESEARCH, 2015, 17
  • [2] The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion
    Danielle Bogan
    Lucio Meile
    Ahmed El Bastawisy
    Hend F. Yousef
    Abdel-Rahman N. Zekri
    Abeer A. Bahnassy
    Wael M. ElShamy
    BMC Cancer, 17
  • [3] The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion
    Bogan, Danielle
    Meile, Lucio
    El Bastawisy, Ahmed
    Yousef, Hend F.
    Zekri, Abdel-Rahman N.
    Bahnassy, Abeer A.
    ElShamy, Wael M.
    BMC CANCER, 2017, 17
  • [4] BRCA1-IRIS overexpression promotes formation of aggressive breast cancers
    ElShamy, Wael M.
    Shimizu, Yoshiko
    Luk, Hugh
    Horio, David
    Miron, Penelope
    Griswold, Michael
    Iglehart, Dirk
    Hernandez, Brenda
    Killeen, Jeffrey
    CANCER RESEARCH, 2012, 72
  • [5] BRCA1-IRIS Overexpression Promotes Formation of Aggressive Breast Cancers
    Shimizu, Yoshiko
    Luk, Hugh
    Horio, David
    Miron, Penelope
    Griswold, Michael
    Iglehart, Dirk
    Hernandez, Brenda
    Killeen, Jeffrey
    ElShamy, Wael M.
    PLOS ONE, 2012, 7 (04):
  • [6] BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin
    Paul, B. T.
    Blanchard, Z.
    Ridgway, M.
    ElShamy, W. M.
    ONCOGENE, 2015, 34 (23) : 3036 - 3052
  • [7] BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin
    B T Paul
    Z Blanchard
    M Ridgway
    W M ElShamy
    Oncogene, 2015, 34 : 3036 - 3052
  • [8] BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin
    Paul, Bibbin T.
    Blanchard, Zannel
    Ridgway, Mildred
    ElShamy, Wael M.
    CLINICAL CANCER RESEARCH, 2015, 21
  • [9] BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions
    Sinha, Abhilasha
    Paul, Bibbin T.
    Sullivan, Lisa M.
    Sims, Hillary
    El Bastawisy, Ahmed
    Yousef, Hend F.
    Zekri, Abdel-Rahman N.
    Bahnassy, Abeer A.
    ElShamy, Wael M.
    ONCOTARGET, 2017, 8 (06) : 10114 - 10135
  • [10] Promoter usage of BRCA1-IRIS
    Anders Kvist
    Carlos Rovira
    Åke Borg
    Patrik Medstrand
    Nature Cell Biology, 2005, 7 : 325 - 326
12345